1,721,546 research outputs found
Polycarbocyclic Architectures: Tridimensional Rigid Structures from Simple Small Molecules
No full textXXXIV "A. Corbella" Summer Schoo
La gravidanza: gestione clinica ed outcome
No full textAffronta il problema della gestione delle gravidanze nelle donne affette da trombocitemia essenziale; valuta le diverse possibilità terapeutiche in questi cas
Sindromi mieloproliferative croniche: La trombocitemia essenziale
No full textEssential thrombocythemia (ET) is a clonal
myeloproliferative disorder characterized by sustained
increase in platelet number and tendency for thromboembolism.
A somatic point mutation that causes a constitutive
activation of the JAK2 gene is found in one in two ET
patients. ET is more common in women, its incidence
being 0.6–2.5/100,000 patient/year and the median age at
diagnosis is 65–70 years. ET can affect all age groups,
including children (0.09 cases/year), and is often diagnosed
in the third–fourth decade of life. Rare cases of familial ET
have been reported. Miscarriages are 3–4 times more
common among women with ET than in the general population,
especially in patients carrying JAK2V617F.
Microvascular disturbances are typical of ET, but a major
thrombosis (2/3 arterial and 1/3 venous; 1, 2–3% patient/
year) is the main cause of morbidity and mortality. Age
over 60 years and/or previous thrombosis are validated risk
factor for thrombosis. Hemorrhages occur in 0.33% patient/
year, mainly in those with a platelet count over
1,500 9 109/L. Progression to myelofibrosis and leukemia
is more common in patients carrying the JAK2V617F
mutation, and is estimated to occur in 0.16% and 0.12%
patient/year, respectively. The ET-related mortality ratio
with respect to the general population is 1:1, while for
polycythemia vera it is 1.6:1. Low-dose aspirin is useful for
microvascular disturbances, and in the primary and secondary
prevention of major thrombosis in high-risk
patients, but it is not recommended in patients with a
platelet count over 1,500 9 109/L. Hydroxyurea is used as
first-line treatment in high-risk patients. Other drugs
available are alpha-interferon, anagrelide, pipobroman and
busulphan
Essential thrombocythemia: past and present.
No full textEssential thrombocythemia (ET) is a clonal myeloproliferative disorder characterized by sustained increase in platelet number and tendency for thromboembolism. A somatic point mutation that causes a constitutive activation of the JAK2 gene is found in one in two ET patients. ET is more common in women, its incidence being 0.6-2.5/100,000 patient/year and the median age at diagnosis is 65-70 years. ET can affect all age groups, including children (0.09 cases/year), and is often diagnosed in the third-fourth decade of life. Rare cases of familial ET have been reported. Miscarriages are 3-4 times more common among women with ET than in the general population, especially in patients carrying JAK2V617F. Microvascular disturbances are typical of ET, but a major thrombosis (2/3 arterial and 1/3 venous; 1, 2-3% patient/year) is the main cause of morbidity and mortality. Age over 60 years and/or previous thrombosis are validated risk factor for thrombosis. Hemorrhages occur in 0.33% patient/year, mainly in those with a platelet count over 1,500 x 10(9)/L. Progression to myelofibrosis and leukemia is more common in patients carrying the JAK2V617F mutation, and is estimated to occur in 0.16% and 0.12% patient/year, respectively. The ET-related mortality ratio with respect to the general population is 1:1, while for polycythemia vera it is 1.6:1. Low-dose aspirin is useful for microvascular disturbances, and in the primary and secondary prevention of major thrombosis in high-risk patients, but it is not recommended in patients with a platelet count over 1,500 x 10(9)/L. Hydroxyurea is used as first-line treatment in high-risk patients. Other drugs available are alpha-interferon, anagrelide, pipobroman and busulphan
High dose intravenous immunoglobulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura
No full textI.F. 38,57
Nurses’ perception of junior doctors activity in an internal medicine ward of a large teaching hospital.
No full text
- …
